Clinical Trials Directory

Trials / Completed

CompletedNCT00602849

Bioequivalency Study of Sertraline Under Fasting Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fasting Conditions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
38 (actual)
Sponsor
Roxane Laboratories · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.

Conditions

Interventions

TypeNameDescription
DRUGSertraline

Timeline

Start date
2003-06-01
Primary completion
2003-07-01
Completion
2003-07-01
First posted
2008-01-28
Last updated
2018-01-23

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00602849. Inclusion in this directory is not an endorsement.